PortfoliosLab logo
Axcella Health Inc. (AXLA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US05454B1052

CUSIP

05454B105

IPO Date

May 9, 2019

Highlights

Market Cap

$1.18M

EPS (TTM)

-$18.25

Target Price

$10.87

Short %

5.91%

Short Ratio

0.75

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
AXLA vs. CVNA AXLA vs. OLMA
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period


AXLA

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.86%

1M

8.72%

6M

-2.74%

1Y

11.65%

5Y*

15.28%

10Y*

10.67%

*Annualized

Monthly Returns

The table below presents the monthly returns of AXLA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20240.00%0.00%
2023107.63%-14.68%-17.27%-16.25%-2.54%-44.28%-16.99%27.48%80.78%-47.61%-16.27%0.00%-44.06%
2022-18.18%10.53%35.98%-33.07%23.26%-4.25%-6.90%30.16%-30.49%-29.82%-29.97%-61.03%-84.33%
20214.82%4.78%-16.49%-13.03%-22.95%25.71%-15.21%7.35%-18.36%7.38%-8.75%-28.42%-59.73%
202020.70%-22.21%-9.16%36.26%28.76%-7.83%-18.81%11.36%-7.60%-8.23%34.43%-8.95%29.43%
20193.41%-34.76%-8.92%-18.28%-18.33%-6.54%-24.39%0.25%-70.94%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Axcella Health Inc. (AXLA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Axcella Health Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


Axcella Health Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Axcella Health Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Axcella Health Inc. was 99.26%, occurring on Aug 25, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.26%Jun 5, 20191065Aug 25, 2023
-4.79%May 22, 20195May 29, 20193Jun 3, 20198
-2.41%May 15, 20191May 15, 20194May 21, 20195

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Axcella Health Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Axcella Health Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 100.0% positive surprise.


-1.20-1.00-0.80-0.60-0.40-0.200.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJuly0
-1.25
Actual
Estimate

Valuation

The Valuation section provides an overview of how Axcella Health Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AXLA relative to other companies in the Biotechnology industry. Currently, AXLA has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AXLA in comparison with other companies in the Biotechnology industry. Currently, AXLA has a P/B value of 19.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items